Figure 1: A computed tomography angiography (CTA) study performed for transcatheter aortic valve replacement planning. Interventional imagers created and interpret these images as part of the heart team.
Figure 2: A patient-specific 3-D design (A) and model (B) of a medial paravalvular leak (PVL) in a patient with a surgically implanted mechanical mitral valve. Interventional imagers created and interpret these images as part of the heart team.
Figure 3: MitraClip implantation at A2-P2 in a patient with severe mitral regurgitation (MR). Interventional imagers created and interpret these images as part of the heart team.
Figure 4: Transcatheter mitral valve-in-valve intervention with a Sapien 3 valve in a patient with a failed bioprosthesis. Interventional imagers created and interpret these images as part of the heart team.

Recent months have signaled a new and exciting era in the dynamic world of structural heart disease (SHD).

Orchestra BioMed Inc. has secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Virtue Sirolimus-Eluting Balloon for the treatment of coronary in-stent restenosis (ISR).

Boston Scientific Receives FDA Approval for Lotus Edge Aortic Valve System
This is an angiographic view of a deployed transcatheter Lotus aortic valve.

Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) approval for the Lotus Edge Aortic Valve System. Delivered via a minimally invasive procedure, this transcatheter aortic valve replacement (TAVR) technology is approved for patients with severe aortic stenosis who are considered at high risk for surgical valve replacement via open heart surgery.

Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may help predict who will be readmitted to the hospital within a month, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for patients with valvular heart disease.

The Medicare Hospital Insurance (HI) Trust Fund, which funds Medicare Part A, will only be able to pay full benefits for Medicare beneficiaries until 2026, according to the 2019 annual report from the Medicare Board of Trustees. The Supplementary Medical Insurance (SMI) Trust Fund, which funds Medicare Part B and D, is expected to be adequately financed in all years, but the aging population and rising healthcare costs are projected to grow SMI costs from 2.1 percent of gross domestic product (GDP) in 2018 to approximately 3.7 percent of GDP in 2038.

SCAI SHOCK: Treating the Spectrum of Cardiogenic Shock

SCAI SHOCK: Treating the Spectrum of Cardiogenic Shock aims to provide a comprehensive review of the definition, diagnosis, and management of cardiogenic shock across the spectrum of care, including different etiologies of shock and various presentation settings from the emergency room to cath lab, community hospital to a large academic center. An overview of shock initiatives, the spectrum of shock, and systems of care will be provided.

New guidelines that classified more children as having elevated blood pressure  are better at predicting which kids are likely to develop heart disease when they reach adulthood, according to new research in the American Heart Association’s journal Hypertension. The guidelines were issued by the American Academy of Pediatrics (AAP) in 2017 and endorsed by the American Heart Association.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now